This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Robert Steyer

Special to TheStreet.com

Robert Steyer, who joined TheStreet.com in July 2003, has written about the business of science, medicine and health care for the St. Louis Post-Dispatch and the Newark Star-Ledger. He also has been a reporter for Fortune, an editor at CFO Magazine and an assistant business editor at the Tampa Tribune.

He has a B.A. in government from Oberlin College and an M.B.A. from New York University.

Robert Steyer
By This Author:
« Back
Page 1 of 148
Article

Are Fund Managers Better Than Their Funds?

By Robert Steyer

For investors still cringing at their IRAs, 401(k)s or taxable mutual funds and exchange-traded funds, are you ready to take a chance on the companies that have brought you so many unhappy returns?

04:51PM 04/20/09

Article

Can Regional Brokers Keep Outperforming?

By Robert Steyer

The regionals may not have as much recognition as the mammoth securities firms, but they won't be receiving as many unwanted headlines either.

10:49AM 02/16/09

Article

Wyeth Deal's Big, but Pfizer Still Needs a Blockbuster

By Robert Steyer

If Pfizer's looking for the next Lipitor, it probably hasn't found it with the acquisition of Wyeth.

04:43PM 01/26/09

Article

Cosmetic Surgery Stocks Keep Stiff Upper Lip

By Robert Steyer

Allergan, Mentor and Medicis have struggled in the past year, but if the economy improves, share prices could, too.

05:05PM 10/28/08

Article

For Abbott, Diversity Remains Paramount

By Robert Steyer

When it comes to investing in big pharmaceutical stocks, it's hard to top this company, especially as its peers continue to suffer.

01:06PM 08/21/08

Article

Legal Questions Still Dogging Wyeth

By Robert Steyer

The company continues to wrestle with the dilemma surrounding the drugs Premarin, Prempro and Premphase. Plaintiffs' lawyers have filed approximately 5,400 lawsuits.

12:37PM 07/21/08

Article

Baxter International Hiding in Plain Sight

By Robert Steyer

In the past five years, its stock has more than tripled, easily outperforming the S&P 500 and the Amex Index of large drug stocks. Is anyone paying attention?

06:59AM 07/01/08

Article

Generic-Drug Stocks Still Under the Weather

By Robert Steyer

Shares of most major generic-drugmakers have traded below the S&P 500 for the 12 months ended May 23, and that index was off nearly 10%.

01:40PM 06/05/08

Article

Need Defense? Think Medical Supplies

By Robert Steyer

Companies such as C.R. Bard and Becton Dickinson might not be the most glamorous names, but their slow and steady performances may win the race.

06:44AM 04/11/08

Article

The Real Winners of Drug Experimentation

By Robert Steyer

The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.

06:59AM 04/03/08

« Back
Page 1 of 148

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs